SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. by TOMITA Issei & 富田 一聖
SGLT2 Inhibition Mediates Protection from















(C) 2020 Elsevier Inc. All rights reserved. 
ArticleSGLT2 Inhibition Mediates Protection from Diabetic
Kidney Disease by Promoting Ketone Body-Induced
mTORC1 InhibitionGraphical AbstractHighlightsd Energy metabolism shifts from lipolysis to ketolysis in
damaged kidneys
d mTORC1 hyperactivation leads to impaired renal lipolysis
and subsequent renal damage
d Ketone body supplementation ameliorates renal damage by
blocking mTORC1 signaling
d SGLT2 inhibitor-mediated renoprotection involves mTORC1
inhibition by ketone bodiesTomita et al., 2020, Cell Metabolism 32, 404–419
September 1, 2020 ª 2020 Elsevier Inc.
https://doi.org/10.1016/j.cmet.2020.06.020Authors
Issei Tomita, Shinji Kume,
Sho Sugahara, ..., Hisakazu Ogita,





SGLT2 inhibitors have been shown to
offer potent renoprotection against
diabetic kidney disease. But the
mechanism for this effect has been
unclear. Here, Tomita et al. report that the
drugs promote elevation of ketone
bodies, which subsequently inhibit
mTORC1 in the proximal renal tubules,
explaining their protective effects on
this organ.ll
llArticle
SGLT2 Inhibition Mediates Protection
from Diabetic Kidney Disease by Promoting
Ketone Body-Induced mTORC1 Inhibition
Issei Tomita,1 Shinji Kume,1,8,* Sho Sugahara,1 Norihisa Osawa,1 Kosuke Yamahara,1 Mako Yasuda-Yamahara,1
Naoko Takeda,1,2 Masami Chin-Kanasaki,1,2 Tatsuroh Kaneko,3 Eric Mayoux,4 Michael Mark,4 Motoko Yanagita,5,6
Hisakazu Ogita,7 Shin-ichi Araki,1,2 and Hiroshi Maegawa1,*
1Department of Medicine, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan
2Division of Blood Purification, Shiga University of Medical Science Hospital, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan
3Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
4CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach an der Riss 88397,
Germany
5Department of Nephrology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan
6Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan
7Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology, Shiga University of Medical Science,
Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan
8Lead Contact
*Correspondence: skume@belle.shiga-med.ac.jp (S.K.), maegawa@belle.shiga-med.ac.jp (H.M.)
https://doi.org/10.1016/j.cmet.2020.06.020SUMMARYSGLT2 inhibitors offer strong renoprotection in subjects with diabetic kidney disease (DKD). But the mech-
anism for such protection is not clear. Here, we report that in damaged proximal tubules of high-fat diet-fed
ApoE-knockout mice, a model of non-proteinuric DKD, ATP production shifted from lipolysis to ketolysis
dependent due to hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1). We further
found that empagliflozin raised endogenous ketone body (KB) levels, and thus its use or treatment with 1,3-
butanediol, a KB precursor, prevented decreases in renal ATP levels and organ damage in the mice. The re-
noprotective effect of empagliflozin was abolished by gene deletion of Hmgcs2, a rate-limiting enzyme of
ketogenesis. Furthermore, KBs attenuated mTORC1-associated podocyte damage and proteinuria in dia-
betic db/db mice. Our findings show that SGLT2 inhibition-associated renoprotection is mediated by
an elevation of KBs that in turn corrects mTORC1 hyperactivation that occurs in non-proteinuric and protei-
nuric DKD.INTRODUCTION
Diabetic kidney disease (DKD) has long been recognized as be-
ing associated with progressive proteinuria (de Zeeuw et al.,
2004), and preventing massive proteinuria due to glomerular
damage remains a challenge in the management of DKD. EvenContext and Significance
SGLT2 inhibitors, an important class of anti-diabetes drugs, hav
a critical comorbidity of diabetes. But how they offer such pr
Kume, and their colleagues show that SGLT2 inhibitors promo
The ketone bodies, in turn, were shown to act on kidney cells
ergy-sensing intracellular pathway, allowing better function of
supplementation with ketone bodies, even in non-diabetic m
broad implications for the potential treatment of kidney patho
404 Cell Metabolism 32, 404–419, September 1, 2020 ª 2020 Elsevieso, the clinical manifestation of DKD has continued to evolve
with an increase in the prevalence of nonproteinuric DKD (Afkar-
ian et al., 2016; Kume et al., 2019)—an emerging issue that
requires a novel therapeutic strategy. Although the exact mech-
anism underlying nonproteinuric DKD remains unresolved,
atherosclerosis- and hypoxia-related renal tubular damagee been found to offer potent protection from kidney disease,
otection has not been clear. Here, Hiroshi Maegawa, Shinji
te the elevation of ketone bodies by enhancing ketogenesis.
where they inhibit the excess activation of an important en-
the organ. Such an effect could be replicated by exogenous











Figure 1. ATP Production Shifts from Lipolysis Dependence to Ketolysis Dependence in PTECs of HFD-Fed ApoE–/– Mice
(A) En face analysis of aorta in ND-fed ApoE+/+ mice and HFD-fed ApoE/ mice.
(B) Representative images of peritubular capillary density determined with CD31 immunostaining (scale bar, 50 mm) and quantitative analysis (20 areas permouse
were analyzed, n = 5–6).
(C) Renal blood flow and quantitative analysis (n = 9 areas per group).
(D) Plasma cystatin C levels.
(E and F) Representative images of PAS and fibronectin staining in glomeruli (scale bar, 25 mm) and scanning electron microscopic analysis of podocytes (scale
bar, 2 mm) (E), and quantitative analysis of glomerular size, mesangial area, and fibronectin-positive area (20 glomeruli per mouse were analyzed, n = 5–6) (F).
(G) Urinary albumin excretion levels.
(H) Representative images of H&E staining, TUNEL staining, and immunostaining of fibronectin and F4/80 in renal tubulointerstitial lesions (scale bar, 50 mm)
(20 areas per mouse were analyzed, n = 5–6).
(I) Quantitative analysis of TUNEL-positive cell number, fibronectin-positive area, and F4/80-positive cell number in tubulointerstitial lesions.
(J) ATP levels in renal cortex samples.
(legend continued on next page)
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Article(rather than glomerular damage) is suggested to be associated
with this type of DKD (Mimura and Nangaku, 2010; Shimizu
et al., 2014; Singh et al., 2008). Thus, in addition to developing
additional therapies to reduce proteinuria, protecting proximal
tubular epithelial cells (PTECs) against atherosclerosis-mediated
systemic damage may provide an improved means to improve
outcomes in individuals with DKD.
Growing evidence from recent large clinical trials has demon-
strated that inhibitors of sodium glucose cotransporter 2 (SGLT2)
reduce the risk of heart failure and improve renal endpoints in in-
dividuals with diabetes beyond their glucose-lowering effect
(Neal et al., 2017; Wanner et al., 2016; Wiviott et al., 2019).
Furthermore, sub-analysis of these trials indicated that the inhib-
itors slowed the decline of renal function for both proteinuric and
nonproteinuric DKD (Cherney et al., 2017; Neuen et al., 2019).
Thus, revealing the mechanism underlying SGLT2 inhibitor-
mediated renoprotection should provide novel insights into the
pathogenesis of both these forms of DKD.
Several reno- and cardioprotective mechanisms of SGLT2 in-
hibitors have been proposed, such as amelioration of tubuloglo-
merular feedback (Kidokoro et al., 2019), hematocrit elevation
(Mazer et al., 2020; Sano et al., 2016), antioxidant properties (Ka-
mezaki et al., 2018; Tanaka et al., 2018), recruitment of progen-
itor cells (Hess et al., 2019), and vascular remodeling (Zhang
et al., 2018). In addition, enhanced ketone body utilization in
tissuesmay be involved in SGLT2 inhibitor-mediated cardio-pro-
tection (Ferrannini et al., 2016; Mudaliar et al., 2016). Further-
more, accumulating evidence demonstrates that enhancing ke-
tone body levels can promote beneficial effects on health, such
as longer life expectancy (Newman et al., 2017; Roberts et al.,
2017), enhanced endurance capacity (Cox et al., 2016), and local
tissue repair (Cheng et al., 2019). However, the role of ketone
body metabolism in SGLT2 inhibitor-mediated cardioprotection
is still under debate (Lopaschuk and Verma, 2016), and its role in
renoprotection has not been elucidated.
ATP production is essential for maintaining cell survival and
function. PTECs depend largely on lipolysis for ATP production
under physiological conditions, whereas the impairment of lipol-
ysis-dependent ATP production is associated with the progres-
sion of kidney diseases, including DKD (Kang et al., 2015; Ta-
naka et al., 2011). Given that ketone bodies are an energy
source, ameliorating defective energy metabolism by increasing
ketone body levels in damaged PTECs may become a novel
therapy for kidney diseases.
Altered intracellular nutrient signals are also involved in the
pathogenesis of DKD (Kume et al., 2012). Of these signals, hy-
peractivation of the mechanistic target of rapamycin complex 1
(mTORC1), which is activated under a hyper-nutrient state, has
been reported to be strongly associated with both PTEC and po-
docyte damage in DKD (Gödel et al., 2011; Inoki et al., 2011; Ku-
wagata et al., 2016), suggesting that inhibition of overactive
mTORC1 signaling may represent a therapy for nonproteinuric
and proteinuric DKD. Ketone bodies have recently attracted
greater attention because this metabolite can function not only(K) Protocol to examine energy dependency on oleate or b-OHB in isolated PTEC
(L) ATP levels after treatment with either oleate or b-OHB in isolated PTECs.
(M) Immunostaining of CPT1a and Scot in kidney samples (scale bar, 50 mm).
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.
406 Cell Metabolism 32, 404–419, September 1, 2020as an ATP source, particularly during fasting, but also as a direct
modulator of intracellular nutrient signals (Puchalska and Craw-
ford, 2017). Thus, we hypothesized that, in addition to being a
direct energy source for damaged PTECs, ketone bodies pre-
vent PTEC and podocyte damage by inhibiting mTORC1
signaling as a signal mediator of fasting, and that thismechanism
may explain how SGLT2 inhibitors mediate renoprotection.
The present study was designed to verify this hypothesis using
both high-fat diet (HFD)-fed ApoE knockout (ApoE/) mice as a
model of nonproteinuric DKD with atherosclerosis and db/db
mice as a model of proteinuric DKD. We report here that ketone
bodies exert renoprotective properties by inhibiting mTORC1
signaling in PTECs and podocytes, and that this at least partially
explains the mechanism of SGLT2 inhibitor-mediated renopro-
tection in nonproteinuric and proteinuric DKD.
RESULTS
ATP Production Shifts from a Lipolysis to a Ketolysis
Dependence in PTECs of HFD-Fed ApoE–/– Mice
HFD-fed ApoE/mice (aged 34 weeks) showed obesity-related
hyperglycemia when compared with that of normal diet (ND)-fed
ApoE+/+ mice (183 ± 15 mg/dL versus 118 ± 12 mg/dL, p < 0.05).
HFD-fed ApoE/ mice developed aortic atherosclerosis, and
lower CD31-positive peritubular capillary density and renal blood
flow (Figures 1A–1C). To evaluate renal function, we measured
plasma cystatin C levels in mice (Leelahavanichkul et al.,
2014). HFD-fed ApoE/ mice exhibited renal dysfunction
defined by high levels of plasma cystatin C (Figure 1D). In this
model, we found glomerular hypertrophy and mesangial expan-
sion with fibrosis (Figures 1E and 1F); however, podocyte dam-
age, as determined by scanning electron microscopy, was not
detected (Figure 1E), and albuminuria was very mild (Figure 1G).
In contrast to mild albuminuria, PTEC damage with vacuolar
changes, as based on hematoxylin and eosin (H&E) staining,
and apoptosis, as well as tubulointerstitial fibrosis and inflamma-
tion, were severe in the mice (Figures 1H and 1I). Thus, HFD-fed
ApoE/ mice exhibited a renal phenotype of nonproteinuric
renal dysfunction with relatively advanced tubulointerstitial le-
sions accompanied bymacro- andmicrovascular damage rather
than a renal phenotype indicative of massive proteinuria. We
believe this mouse model successfully reflects human nonpro-
teinuric DKD, which can be associated with atherosclerosis.
Renal ATP levels in the kidneys of HFD-fedApoE/micewere
lower than those of ND-fed ApoE+/+ mice (Figure 1J). When we
analyzed dependence on fatty acids (oleate) and ketone bodies
(b-hydroxybutyrate; b-OHB) for ATP production using isolated
PTECs from either ND-fed ApoE+/+ or HFD-fed ApoE/ mice
(Figure 1K), ATP production in PTECs from healthy and damaged
kidneys was dependent on lipolysis and ketolysis, respectively
(Figure 1L). When compared to ND-fed ApoE+/+ mice, HFD-fed
ApoE/ mice exhibited lower renal expression of carnitine pal-
mitoyltransferase 1a (CPT1a), a lipolytic enzyme, and higher








Figure 2. Ketone Body Supplementation with 1,3-Butanediol (1,3-BD) Ameliorates Kidney Injury in HFD-Fed ApoE–/– Mice
(A) Study protocol for examining the effect of 1,3-BD on the renal phenotype of HFD-fed ApoE/ mice.
(B and C) Daily profiles of blood glucose (B) and b-OHB (C) (n = 5–7).
(D) Body weight change during the experimental period.
(E) Representative images of en face analysis to detect atherosclerosis, and quantitative data (n = 5 total samples analyzed, per group).
(F) Representative images of peritubular capillary density determined with CD31 immunostaining (scale bar, 50 mm) and quantitative analysis (20 areas per mouse
were analyzed, n = 5–7).
(G) Renal blood flow and quantitative analysis (n = 9 areas per group).
(legend continued on next page)
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Article(Scot), a ketolysis-related enzyme. (Figure 1M), suggesting that
the energy generation of damaged PTECs shifted from lipolysis
to ketolysis dependence.
Supplementation with 1,3-Butanediol (1,3-BD)
Ameliorates Kidney Injury in HFD-Fed ApoE–/– Mice
1,3-BD is a chemical ketone body precursor that can be orally
administered and is converted to b-OHB in the liver in an insu-
lin-independent manner. We first confirmed that 1,3-BD
increased blood b-OHB levels without affecting blood glucose
levels in control C57BL/6 mice (Figures S1A–S1C) and did not
show any evidence of renotoxicity (Figures S1D and S1E). Sub-
sequently, 1,3-BD was administered to HFD-fed ApoE/ mice
(Figure 2A). 1,3-BD treatment significantly increased blood
b-OHB levels without affecting blood glucose levels in HFD-fed
ApoE/ mice (Figures 2B and 2C). This treatment did not alter
body weight gain, blood pressure, blood pH, or lipid profiles of
HFD-fed ApoE/ mice (Figure 2D; Table S1). Furthermore,
1,3-BD treatment did not improve macro- and intrarenal micro-
vascular damage, and accordingly did not alter reduced renal
blood flow in HFD-fed ApoE/ mice (Figures 2E–2G).
In contrast to the effect on vascular damage, 1,3-BD treatment
significantly prevented glomerular damage, tubular vacuolar for-
mation, tubulointerstitial fibrosis and inflammation, PTEC
apoptosis, mitochondrial morphological changes (round shape
and fragmentation) in PTECs, and subsequent renal dysfunction
as assessed by measuring plasma cystatin C levels (Figures 2H–
2J and S1F). Furthermore, 1,3-BD treatment restored renal ATP
levels in HFD-fed ApoE/mice (Figure 2K), and renal ATP levels
were inversely correlated with plasma cystatin C levels in HFD-
fed ApoE/ mice treated with or without 1,3-BD (Figure 2L).
These findings suggest that increasing ketone bodies amelio-
rates vascular damage-related kidney injury in diabetic mice,
which is accompanied by restoration of renal ATP production.
Empagliflozin Restores Renal ATP Levels and
Ameliorates Kidney Injury in HFD-Fed ApoE–/– Mice
When we examined the effects of empagliflozin, an SGLT2 inhib-
itor used clinically, on kidney injury in HFD-fed ApoE/mice un-
der ad libitum feeding (Figure S2A), we found that blood glucose
levels were lower than the non-treated group (Figure S2B), but
blood ketone body levels were not different, and vascular dam-
age-related renal tissue damage and dysfunction were not
ameliorated (Figures S2C–S2E).
Endogenous ketone body production from the liver is physio-
logically suppressed by postprandial insulin action, and
increased blood ketone levels by an SGLT2 inhibitor were pre-
dominantly observed after overnight fasting in human subjects
(Ferrannini et al., 2016). Thus, we considered that complete fast-
ing during sleep is required to increase plasma ketone body
levels by SGLT2 inhibitors in an animal study.We then performed(H) Representative images of immunostaining of fibronectin in glomeruli (scale ba
5–7).
(I) Representative images of H&E staining, immunostaining of fibronectin and F
quantitative analysis (20 areas per mouse were analyzed, n = 5–7).
(J and K) Plasma cystatin C (J) and renal ATP levels in renal cortex samples (K).
(L) Correlation analysis between plasma cystatin C and renal ATP levels.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01. NS indicates no sig
408 Cell Metabolism 32, 404–419, September 1, 2020a preliminary examination of the effect of empagliflozin treat-
ment, along with complete dietary withdrawal for 8 h during a
sleeping period, on blood glucose and b-OHB levels in
C57BL/6 mice (Figure S2F). We confirmed that this protocol of
empagliflozin administration successfully increased blood
b-OHB levels during fasting, without altering fasting blood
glucose levels and any renal adverse effects (Figures S2G–S2J).
Thus, we verified the effectiveness of empagliflozin in kidney
injury in HFD-fed ApoE/ mice using this protocol (Figure 3A).
This treatment significantly decreased blood glucose levels
and increased ketone body levels after fasting in 26- and 30-
week-old HFD-fed ApoE/ mice (Figures 3B, 3C, S2K, and
S2L). Long-term treatment with empagliflozin lowered body
weight but did not affect blood pressure, plasma pH, or lipid
profiles in HFD-fed ApoE/ mice (Figure 3D; Table S2). This
strategy suppressed the development of aortic atherosclerosis
(Figure 3E), whereas CD31-positive peritubular capillary density
loss and renal blood flow were not restored (Figures 3F and 3G).
When we analyzed aortic atherosclerosis and peritubular capil-
lary density in 26-week-old HFD-fed ApoE/mice (before start-
ing the empagliflozin treatment), aortic atherosclerosis was still
mild, but peritubular capillary density loss was already estab-
lished when compared with those in 34-week-old HFD-fed
ApoE/ mice (Figure S2M). Thus, it was possible that empagli-
flozin treatment prevented further development of aortic athero-
sclerosis from 26 to 34weeks of age, andwas not able to reverse
the established renal peritubular capillary loss.
Even in kidneys where renal blood flow was not restored in
34-week-old HFD-fed ApoE/ mice, empagliflozin prevented
glomerular damage, tubular cell alteration and apoptosis, tubu-
lointerstitial fibrosis and inflammation, mitochondrial abnormal-
ities in PTECs, and elevation of plasma cystatin C levels (Figures
3H–3J and S2N). Furthermore, empagliflozin treatment restored
renal ATP levels (Figure 3K), which were associated with
improved renal function (Figure 3L). Thus, SGLT2 inhibitor
treatment showed a similar renoprotective effect as 1,3-BD
administration.
Hmgcs2 Deficiency Abolishes Empagliflozin-Mediated
Renoprotection in HFD-Fed ApoE–/– Mice
To confirm the importance of endogenous ketogenesis in the re-
noprotection elicited by SGLT2 inhibition, we generated mice
lacking the Hmgcs2 gene, which encodes the rate-limiting
enzyme of endogenous ketogenesis, using the Crispr-CAS9 sys-
tem to delete a part of exon 2 (Figure 4A). The resulting frameshift
ofHmgcs2 caused complete deletion of hepatic Hmgcs2 protein
expression (Figure 4B), and impaired both fasting-dependent
and SGLT2 inhibitor-dependent ketogenesis without affecting
glucose metabolism (Figures 4C–4F). We found that Hmgcs2
deficiency alone neither exacerbated kidney injury nor
decreased renal ATP levels in HFD-fed ApoE/ mice, althoughr, 25 mm) and quantitative analysis (20 glomeruli per mouse were analyzed, n =











Figure 3. Empagliflozin Restores Renal ATP levels and Ameliorates Kidney Injury in HFD-Fed ApoE–/– Mice
(A) Study protocol for examining the effect of empagliflozin (Empa) on the renal phenotype of HFD-fed ApoE/ mice.
(B and C) Changes in blood glucose (B) and b-OHB (C) during 8-h fasting (n = 5–8).
(D) Body weight change during the experimental period.
(E) Representative images of en face analysis of the aorta and quantitative analysis (n = 5 total samples analyzed per group).
(F) Representative images of peritubular capillary density determined with CD31 immunostaining (scale bar, 50 mm) and quantitative analysis (20 areas per mouse
were analyzed, n = 5–8).
(G) Renal blood flow and quantitative analysis (n = 9 areas per group).
(legend continued on next page)
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Articlethe gene deletion decreased blood b-OHB levels without
affecting blood glucose levels (Figures S3A–S3F), suggesting
that further lowering the originally low ketone body concentration
by Hmgcs2 deficiency did not aggravate renal damage.
We next generated double-knockout mice lacking both ApoE
and Hmgcs2 genes. The double-knockout mice were treated
with empagliflozin under HFD-fed conditions with 8-h fasting
daily, to examine the effect ofHmgcs2 gene deletion on empagli-
flozin-mediated renoprotection in HFD-fed ApoE/ mice (Fig-
ure 4G). Metabolic characteristics of the study groups are shown
in Table S3. AlthoughHmgcs2 deficiency did not alter changes in
body weight or the anti-atherogenic effect of empagliflozin in
HFD-fed ApoE/ mice (Figures 4H and 4I), deletion of this
gene abolished empagliflozin-mediated renoprotection and
restoration of renal ATP production without affecting the
decrease in CD31-positive peritubular capillary density (Figures
4J–4M and S3G). Thus, enhanced endogenous ketogenesis is
required for the renoprotective action of SGLT2 inhibitors against
vascular damage-related kidney injury.
Hyperactivation of mTORC1 Impairs Renal Lipolysis in
PTECs of HFD-Fed ApoE–/– Mice
We next examined the effect of ketone body supplementation on
the relationship between mTORC1 signaling and renal lipolysis in
DKD, as hyperactivation of mTORC1 signaling is reportedly
involved in both the pathogenesis of DKD (Gödel et al., 2011; Inoki
et al., 2011; Kuwagata et al., 2016) and impairment of lipolysis in
some tissues (Ricoult andManning, 2013). In the kidneysof control
ND-fed ApoE+/+ mice, mTORC1 signaling (as assessed by phos-
phorylation of the S6 protein) was inactive in aquaporin 1
(AQP1)-positive PTECs, but was active in calbindin D28k
(CaBP)-positive distal tubules even under healthy conditions (Fig-
ure 5A). In HFD-fed ApoE/mice, mTORC1 activity in the PTECs
and distal tubules was activated and enhanced, respectively (Fig-
ure 5A). 1,3-BD treatment attenuated mTORC1 signaling in both
PTECs and distal tubules of HFD-fed ApoE/ mice, although it
did not suppress the basal level of mTORC1 activity in distal tu-
bules (Figure 5A). Furthermore, empagliflozin treatment with 8-h
fasting suppressed renal mTORC1 hyperactivation, but this effect
was abolished by deletion of the Hmgcs2 gene (Figure 5A). These
findings were confirmed by immunoblot analysis (Figure 5B).
Rapamycin, an inhibitor of mTORC1, significantly prevented
mTORC1 hyperactivation and recovered fatty acid (oleate)-
derived ATP production, but did not suppress ketolysis-depen-
dent ATP production in PTECs isolated from HFD-fed ApoE/
mice (Figures 5C and 5D). In the kidneys of HFD-fed ApoE/
mice, both 1,3-BD treatment and empagliflozin restored CPT1a
expression but did not affect Scot expression (Figures 5E and
5F). These results suggest that mTORC1 hyperactivation is
associated with decreased renal lipolysis but is not involved in
enhanced renal ketolysis associated with DKD.(H) Representative images of immunostaining of fibronectin in glomeruli (scale b
n = 5–8).
(I) Representative images of H&E staining, TUNEL staining, and immunostaining
quantitative data (20 areas per mouse were analyzed, n = 5–8).
(J and K) Plasma cystatin C (J) and renal ATP levels in renal cortex samples (K)
(L) Correlation analysis between plasma cystatin C and renal ATP levels.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01. NS indicates no sig
410 Cell Metabolism 32, 404–419, September 1, 20201,3-BD and Empagliflozin Ameliorate Kidney Injury and
the Mortality Rate in Tamoxifen-Inducible Kidney
Tubule-Specific Tsc-1 Knockout (Kidney-Tsc1–/–) Mice
To further confirm the effect of ketone bodies on mTORC1 inhi-
bition, we generated kidney-Tsc1/mice using Tsc1f/f mice and
tamoxifen-inducible kidney-specific (Ndrg1 promoter-derived)
CreERT2-expressing mice (Endo et al., 2015). In this mouse
model, hyperactivation of mTORC1 signaling can be induced in
renal tubules after tamoxifen injection as Tsc1 inhibits mTORC1
signaling (Inoki et al., 2012; Saxton and Sabatini, 2017).
We analyzed the effect of 1,3-BD on renal mTORC1 activity
and renal phenotypes of this mousemodel (Figure 6A). Tsc1 defi-
ciency promoted renal hypertrophy, tubular dilatation, and
fibrosis, and it increased serum cystatin C, which was accompa-
nied by enhanced phosphorylation of S6 protein mainly in PTECs
(Figures 6B–6E). 1,3-BD treatment significantly attenuated renal
hyperactivation of mTORC1, and subsequent renal enlargement
and injury (Figures 6B–6E). Furthermore, renal ATP levels in kid-
ney-Tsc1/ mice were lower than those in Tsc1f/f mice, but 1,3-
BD-mediated ketone body supply prevented ATP production in
kidney-Tsc1/ mice (Figure 6F). Kidney-Tsc1/ mice started
to die within 5 weeks after tamoxifen-induced Tsc1 deletion,
but the high mortality rate was not found in kidney-Tsc1/
mice treated with 1,3-BD (Figure 6G).
Pretreatment with rapamycin and b-OHB suppressed hyper-
activation of mTORC1 in Tsc1-deficient cultured PTECs (Fig-
ure 6H). Tsc1 deletion-mediated mTORC1 activation promoted
renal metabolic reprograming, as indicated by a reduction in
lipolysis and an increase in ketolysis (Figure 6I). Pretreatment
with either rapamycin or b-OHB recovered lipolysis, but did not
affect enhanced ketolysis, in Tsc1-deficient PTECs (Figure 6I).
Furthermore, CPT1a expression was lower and Scot expression
was higher in kidneys of kidney-Tsc1/ mice, compared with
control Tsc1f/f mice (Figure S4A). 1,3-BD treatment prevented
a decrease in CPT1a expression without affecting Scot expres-
sion in kidneys of kidney-Tsc1/ mice (Figure S4A).
We also examined the effect of empagliflozin with 8-h fasting
on renal phenotype and mortality rate of kidney-Tsc1/ mice
(Figure 6J). Similar to the results observed with 1,3-BD treat-
ment, empagliflozin suppressedmTORC1 activity in PTECs (Fig-
ure 6K), ameliorated renal hypertrophy and renal dysfunction
(Figures 6L and 7M), and restored renal ATP levels with high
levels of CPT1a expression (Figures 6N and S4B) in kidney-
Tsc1/ mice. Empagliflozin also prevented a high mortality
rate in kidney-Tsc1/ mice (Figure 6O).
1,3-BD Treatment and Empagliflozin Prevent Podocyte
Injury and Massive Proteinuria in Type 2 Diabetic
db/db Mice
As mTORC1 is involved in the development of podocyte injury-
relatedmassive proteinuria in DKD, we hypothesized that ketonear, 25 mm) and quantitative analysis (20 glomeruli per mouse were analyzed,










Figure 4. Hmgcs2 Deficiency Abolishes Empagliflozin-Mediated Renoprotection in HFD-Fed ApoE–/– Mice
(A) Generation of an Hmgcs2 gene-deleted mouse model using the CRISPR-CAS9 system. Two guide RNAs were designed for exon 2 of the gene.
(B) Protein expression of Hmgcs2 in livers of Hmgcs2+/+ and Hmgcs2/ mice.
(C and D) Fasting-dependent changes in blood glucose (C) and b-OHB (D) in Hmgcs2+/+ and Hmgcs2/ mice (n = 4–8).
(E and F) Time-dependent changes in blood glucose (E) and b-OHB (F) after empagliflozin treatment in Hmgcs2+/+ and Hmgcs2/ mice (n = 4–8).
(G) Study protocol for examining the effects of the Hmgcs2 gene deletion on Empa-mediated renoprotection.
(H) Body weight change during the experimental period (n = 7–8).
(I) Representative images of en face analysis of the aorta and quantitative analysis (n = 6 total samples, per group).
(J) Representative images of immunostaining of fibronectin in glomeruli (scale bar, 25 mm) and quantitative analysis (20 glomeruli per mouse were analyzed,
n = 7–8).
(K) Representative images of H&E staining; immunostaining of CD31, fibronectin, and F4/80 in tubulointerstitial lesions (scale bar, 50 mm); and quantitative
analysis (20 areas per mouse were analyzed, n = 7–8).
(L and M) Plasma cystatin C (L) and renal ATP levels in renal cortex samples (M).
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01. NS indicates no significance.
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Figure 5. Hyperactivation of mTORC1 Impairs Renal Lipolysis in PTECs of HFD-Fed ApoE–/– Mice
(A) Immunohistochemistry of pS6 (scale bar, 500 mm) and immunofluorescent staining of pS6 in AQP1-positive PTECs and Calbindin D28k (CaBP)-positive distal
tubules (scale bar, 50 mm).
(B) Representative images of immunoblots for pS6 and S6 in renal cortex samples (n = 5–8 total samples per group analyzed).
(C) Representative images of immunoblots for pS6 and S6 in isolated PTECs (n = 8 total samples per group analyzed).
(legend continued on next page)
ll
Article
412 Cell Metabolism 32, 404–419, September 1, 2020
ll
Articlebody supplementation can prevent podocyte injury in a proteinu-
ric DKD model. In db/dbmice (a proteinuric DKD model) treated
with 1,3-BD (Figure 7A), blood glucose levels were not altered,
whereas b-OHB levels were higher than the non-treated db/db
mice. (Figures S5A and S5B). The treatment reduced massive
albuminuria in db/db mice (Figure 7B). This treatment also
ameliorated fibrosis in both glomerular and interstitial lesions,
alteration of podocyte foot process in scanning electron micro-
scopy, and low number of WT1-positive podocyte (Figures 7C–
7F), which was accompanied by suppression of mTORC1
signaling in podocytes and renal tubules of db/db mice (Figures
7G and S5C). Similarly, empagliflozin with 8-h fasting prevented
mTORC1-associated kidney injury in db/db mice, with a reduc-
tion in blood glucose levels and an increase in b-OHB levels (Fig-
ures 7H–7N and S5D–S5F).
1,3-BD Treatment and Empagliflozin Attenuate Kidney
Injury in Non-Diabetic 5/6 Nephrotomized Mice
Because the renoprotective potency of SGLT2 inhibitors is ex-
pected to occur in non-diabetic kidney diseases, we finally eval-
uated the effect of 1,3-BD administration and empagliflozin
treatment with 8-h fasting on kidney injury in 5/6 nephrectomized
mice (Figure S6A). Blood b-OHB levels were higher in the 5/6
nephrectomized mice treated with either 1,3-BD or empagliflo-
zin, compared with non-treated mice (Figure S6B). The treated
mice exhibited lower blood pressure, albuminuria, and plasma
cystatin C levels (Figures S6C–S6E), with the amelioration of his-
tological damage in both podocytes and tubulointerstitial lesions
(Figures S6F and S6G). These ameliorations were accompanied
by inhibition of mTORC1 signaling in podocytes and PTECs and
maintenance of renal CPT1a expression (Figures S6F and S6G).
Scot expression was lower in the damaged kidneys of 5/6 neph-
rectomized mice, which was not attenuated by the treatments
(Figure S6G). These results were consistent with the results ob-
tained from the series of DKD studies outlined above.
DISCUSSION
Growing evidence suggests that elevated ketone bodies have
various beneficial effects on health such as increased endurance
capacity in athletes and improved cardiac function in heart fail-
ure (Cox et al., 2016; Nielsen et al., 2019). The present study
demonstrated that ketone bodies exert renoprotective action in
DKD and non-DKD models, providing additional support to this
concept. Ketone body utilization increases in skeletal muscles
during exercise and experimentally in damaged heart tissues
(Cox et al., 2016; Nielsen et al., 2019; Schugar et al., 2014;
Winder et al., 1974). Similarly, the present study revealed that
metabolic reprograming, characterized by a shift from lipolysis
to ketolysis, occurred in damaged PTECs. Ketone bodies have
long been considered an undesirable metabolite in diabetes
because of the life-threatening diabetic ketoacidosis in patients
with type 1 diabetes. However, supplying ketone bodies within
an optimal range to organs requiring ketone bodies for mainte-(D) Energy dependency on oleate and b-OHB for the indicated conditions of isol
(E and F) Representative images of immunostaining of CPT1a and Scot, and quan
mouse were analyzed, n = 5–8).
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01. NS indicates no signance of their energy homeostasis is likely to be beneficial for
health.
Although the role of ketone body metabolism in SGLT2 inhib-
itor-mediated organ protection has received significant atten-
tion, its exact role has long been debated (Lopaschuk and
Verma, 2016). In our study, SGLT2 inhibitor treatment under ad
libitum feeding did not increase blood ketone body levels and
failed to show renoprotection. In contrast, treatment with 8-h
daily fasting improved kidney injury, which was accompanied
by an increase in ketone body levels. Furthermore, the renopro-
tective action of an SGLT2 inhibitor was abolished by impaired
ketogenesis in Hmgcs2-deficient mice. Thus, elevated ketone
body levels, as well as the previously proven mechanisms (Ka-
mezaki et al., 2018; Kidokoro et al., 2019; Sano et al., 2016; Ta-
naka et al., 2018; Zhang et al., 2018), are likely to be involved in
the SGLT2 inhibitor-mediated renoprotective effect beyond their
glucose-lowering effect in, at least, animal models.
HFD-fed ApoE/ mice developed tubular cell damage and
renal dysfunction without massive albuminuria and podocyte
injury, representing a model of nonproteinuric DKD with athero-
sclerosis and intrarenal peritubular capillary density loss, sug-
gesting that this model may be an ideal experimental model for
studying vascular damage-related kidney injury with obesity
and hyperglycemia. In this mouse model, empagliflozin amelio-
rated atherosclerosis, but 1,3-BD did not improve atheroscle-
rosis. Systemic improvements, such as body weight reduction
and blood glucose lowering, may be associated with the anti-
atherosclerotic effect of empagliflozin, and ketone bodies
per se are unlikely to have a protective effect against
atherosclerosis.
In previous animal studies, the anti-atherosclerotic effect of
anti-diabetic drugs has been observed in relatively short-term
experiments (Ma et al., 2018; Wang et al., 2017), but human
studies have reported that it takes a long time to see the effect
of lowering blood glucose levels on atherosclerosis (Holman
et al., 2008). As for SGLT2 inhibitors, during the observation
period in human clinical studies, the anti-atherosclerosis effect
of SGLT2 inhibitors was not evident (Neal et al., 2017; Zinman
et al., 2015). However, given that SGLT2 inhibitors ameliorated
atherosclerosis in our present data and previous animal studies
(Dimitriadis et al., 2019; Han et al., 2017), the anti-atherosclerotic
effect via the hypoglycemic effect of the agentsmay be expected
in future follow-up periods in human studies. The explanation for
the difference in anti-atherosclerotic effects of anti-diabetic
drugs between mice and humans remains unknown.
Ketone bodies have recently been seen as a possible meta-
bolic intermediary in caloric restriction. Ketone bodies have
long been recognized as a simple carrier of energy to peripheral
tissues from the liver. However, accumulating evidence sug-
gests that ketone bodies act as signaling modulators (Cheng
et al., 2019; Puchalska and Crawford, 2017). Several intracellular
signals are altered by a ketogenic diet or caloric restriction (Pu-
chalska and Crawford, 2017). Of these, mTORC1 is one of the
signals that can be modulated by these nutrient conditions (Inokiated cells.
titative data of a CPT1a-positive area in tubules (scale bar, 50 mm) (20 areas per
nificance.











Figure 6. 1,3-BD and Empagliflozin Ameliorate Kidney Injury and the Mortality Rate in Tamoxifen-Inducible Kidney Tubule-Specific Tsc-1
Knockout (Kidney-Tsc1–/–) Mice
(A) Study protocol for examining the effect of 1,3-BD on the renal phenotype of kidney-specific Tsc1/ mice.
(B) Macro renal morphology of the indicated groups.
(C) Immunofluorescence of pS6 in AQP1-positive PTECs and Calbindin D28k (CaBP)-positive distal tubules (scale bar, 50 mm).
(D) Representative images of H&E staining and immunostaining of fibronectin (scale bar, 50 mm) (n = 5 total samples per group analyzed).
(E and F) Plasma cystatin C (E) and ATP levels in renal cortex samples (F) (n = 5 per group).
(G) Cumulative survival rate in kidney-specific Tsc1/ mice treated with or without 1,3-BD after tamoxifen-induced Tsc1 deletion (n = 10 per group).
(H) Representative images of immunoblotting of pS6 and S6 in PTECs isolated from the indicated mouse groups (n = 8 total samples per group analyzed).
(legend continued on next page)
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Articleet al., 2012; Saxton and Sabatini, 2017). However, a direct inter-
action between ketone bodies and mTORC1 activity has not
been demonstrated. In this study, b-OHB suppressed mTORC1
signaling directly in cultured Tsc1-deficient PTECs, and 1,3-BD
dramatically improved the survival rate and reduced kidney
injury in kidney-specific Tsc1/ mice. Collectively, ketone
bodies are likely to be endogenous inhibitors of mTORC1
signaling. Although the physiological significance of this interac-
tion remains unclear, it may be globally involved in the benefits of
caloric restriction.
Reprograming in renal energymetabolism, which is character-
ized by impaired lipolysis and enhanced ketolysis, was observed
in the PTECs of HFD-fed ApoE/ mice. Both impaired lipolysis
and hyperactivation of mTORC1 were independently reported to
be involved in the development of kidney diseases (Kang et al.,
2015; Kuwagata et al., 2016). Our data connected the two major
pathogenic changes. Hyperactivation of mTORC1 is responsible
for impaired renal lipolysis in damaged PTECs, and in agreement
with previous findings, mTORC1 hyperactivation plays a central
role in impaired lipolysis in some metabolic tissues (Chakrabarti
et al., 2013; Ricoult and Manning, 2013). Given that restoring
lipolysis capacity has recently garnered greater attention as a
therapeutic target for a variety of obesity-related metabolic dis-
eases, the evidence that ketone bodies can improve lipolysis via
mTORC1 inhibition should provide novel insights into this
research area.
In addition to the effect of ketone bodies on kidney injury in the
non-proteinuric DKDmodel, we examined its role in db/dbmice,
a proteinuric DKD model. The results showed that mTORC1-
associated podocyte damage and massive proteinuria were
attenuated by 1,3-BD and empagliflozin in db/dbmice. Thus, ke-
tone bodies may also be involved in the anti-proteinuric effect of
SGLT2 inhibitors. Furthermore, ketone body supplementation
prevented kidney injury by inhibiting mTORC1 signaling in non-
diabetic 5/6 nephrectomized mice. Renoprotection by ketone
bodies was accompanied by a blood pressure lowering effect,
which is consistent with a previous report (Chakraborty et al.,
2018). Enhanced ketogenesis, as well as enhanced natriuresis,
may be involved in the anti-hypertensive effect of SGLT2 inhibi-
tors. The results from the 5/6 nephrectomized mouse study
further reinforce the concept that SGLT2 inhibitors are also
effective drugs against non-diabetic kidney diseases.
Hyperactivation of mTORC1 is associated with a variety of dis-
eases such as kidney, metabolic, and age-related diseases
(Saxton and Sabatini, 2017). Recently, it was reported that ke-
tone bodies stopped cyst formation in a rodent polycystic kidney
disease model, which was accompanied by mTORC1 inhibition
(Torres et al., 2019). Although evidence demonstrating an inter-
action between ketone bodies and mTORC1 signaling is still
weak, and tissue-specific roles of ketone bodies in the regulation
of mTORC1 signaling remain to be explored, it is possible that(I) Energy dependency on oleate and b-OHB in isolated PTECs under the indicat
(J) Study protocol for examining the effect of empagliflozin on renal phenotypes
(K) Immunofluorescent study of pS6 in AQP1-positive PTECs (scale bar, 50 mm).
(L) Macro renal morphology in the indicated groups.
(M and N) Plasma cystatin C (M) and ATP levels in renal cortex samples (N) (n =
(O) Survival rate in kidney-specific Tsc1/ mice treated with or without Empa af
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.ketone body supplementation may become a promising thera-
peutic strategy against mTORC1-related diseases, including
increasing longevity and improving metabolism in age-related
diseases.
Local ketogenesis has recently been reported to be respon-
sible for tissue repair in intestinal cells (Cheng et al., 2019). Given
that PTECs can produce ketone bodies (Takagi et al., 2016) and
SGLT2 inhibitors enhance renal ketogenesis (Kim et al., 2019),
local ketogenesis in kidneys may be involved in renoprotection
elicited by SGLT2 inhibitors. A kidney-specificHmgcs2-deficient
mouse model may verify this additional hypothesis. Revealing
the roles of local ketone body production in kidney diseases
may contribute to a better understanding of the pathogenesis
of kidney diseases including DKD.
Pimozide is an antipsychotic drug currently in clinical use.
Interestingly, a recent study demonstrated that this drug acted
as a Scot inhibitor and reversed obesity-induced hyperglycemia
in mice by blocking ketolysis in skeletal muscle (Al Batran et al.,
2020). However, based on our results, blocking renal ketolysis
may worsen kidney diseases. Thus, although no serious renal
damage as a side effect of this drug has been clinically reported
so far, whether this drug inhibits renal ketolysis and whether it
adversely affects the long-term renal prognosis of subjects
with chronic kidney disease may be an issue to be resolved in
the future.
In conclusion, we provide a novel link between SGLT2 inhibi-
tion, renal ketone body metabolism, mTORC1 signaling, and
DKD progression (Figure 7O). Although multiple mechanisms
are expected to mediate the renoprotective effects elicited by
SGLT2 inhibitors, its effects on ketone bodies and thus on
damaged PTECs in the models examined here suggest that tar-
geting renal energy metabolism may be a promising avenue in
the treatment of both proteinuric and non-proteinuric DKD.
Limitations of Study
Although impaired renal lipolysis is mediated by mTORC1 acti-
vation, themechanism underlying enhanced ketone body utiliza-
tion in damaged kidneys remains unresolved (another aspect of
renal energy reprograming in DKD). Based on our data, mTORC1
was not associated with this change. Some epigenetic factors,
such as histone modifications, are reportedly associated with
the pathogenesis of DKD (Kato and Natarajan, 2014), which
may be involved in stimulated ketone utilization in damaged kid-
neys. Further examination to elucidate the mechanism underly-
ing the upregulation of Scot expression in damaged kidneys is
required. Second, the detailed molecular mechanism underlying
ketone body-mediated inhibition of mTORC1 signaling remains
unclear. Regulation of signals upstream of mTORC1, such as
AMP-activated protein kinase and translocation of mTORC1 to
lysosomal membranes, were previously reported to be regula-
tory mechanisms of mTORC1 activity (Inoki et al., 2012). Theseed conditions.
of kidney-specific Tsc1/ mice.
6 per group).
ter tamoxifen-induced Tsc1 gene deletion (n = 10 per group).












Figure 7. 1,3-BD Treatment and Empagliflozin Prevent Podocyte Injury and Massive Proteinuria in Type 2 Diabetic db/db Mice
(A) Study protocol for examining the effect of 1,3-BD on the renal phenotype of db/db mice.
(B) Albuminuria at start (left) and end (right) of the experiment (n = 6, each group).
(legend continued on next page)
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Articlemechanisms may be involved in ketone body-mediated
mTORC1 inhibition. A more detailed mechanism of mTORC1-
dependent impairment of renal lipolysis remains unclear,
although an mTORC1-dependent decrease in lipolytic enzyme
expression is likely to be involved. In addition, as mTORC1 reg-
ulates a variety of cellular functions, such as autophagy (Yama-
hara et al., 2013), changes in some cellular processes apart from
lipolysis inhibition may be involved in mTORC1-mediated renal
damage. As a technical concern, we cannot completely exclude
the possibility that Tsc1 deficiency or rapamycin affected path-
ways other than mTORC1, although these strategies have
been widely used to activate and suppress mTORC1 signaling,
respectively. Furthermore, clinical evidence showing an associ-
ation between ketone body elevation in SGLT2 inhibitor treat-
ment and DKD prognosis is still absent. Finally, the molecular
mechanism by which SGLT2 inhibitors lead to upregulation of
blood ketone body levels is still unclear. Solving these issues
should provide further important insights into the pathogenesis
of both metabolic and kidney diseases, and contribute to better
renal prognosis of DKD.STAR+METHODS
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F4/80 BIO-RAD Cat#MCA497GA; RRID: AB_323806
Scot Sigma Aldrich Cat#HPA012047; RRID: AB_1854857
Hmgcs2 Cell Signaling Technology Cat#20940; RRID: AB_2798853
CPT1A Proteintech Cat#15184-1-AP; RRID: AB_2084676
b actin Sigma Aldrich Cat#A5316; RRID: AB_476743
Phospho-S6 (Ser235/236) Cell Signaling Technology Cat#2211; RRID: AB_331679
S6 Ribosomal Protein (S6) (5G10) Cell Signaling Technology Cat#2217; RRID: AB_331355
ECL Anti-mouse IgG, Horseradish Peroxidase-Linked
Whole Antibody
GE Healthcare Cat#NA931; RRID: AB_772210
ECL Anti-Rabbit IgG, Horseradish Peroxidase-Linked
Whole Antibody
GE Healthcare Cat#NA934; RRID: AB_772206
CD31 Dianova GmbH Cat#DIA-310; RRID: AB_2631039
Aquaporin 1 abcam Cat#ab9566; RRID: AB_296494
Calbindin-D-28K Sigma Aldrich Cat#C9848; RRID: AB_476894
WT-1 Santa Cruz Blotechnology Cat#sc-192; RRID: AB_632611
Chemicals, Peptides, and Recombinant Proteins
Oil-Red O Sigma Aldrich Cat#MKCJ3586
Hematoxylin Muto Kagaku Cat#88529
Eosin Muto Kagaku Cat#32081
CLEA Rodent Diet CE-2 (Normal Diet) CLEA Japan CE-2
High fat diet 60% ORIENTAL YEAST N/A
Oleate Sigma Aldrich Cat#01008
Bovine serum albumin Nakarai tesque Cat#M7N0304
Collagenase Type II Life Technologies Cat#17104-019
Hyaluronidase FUJIFILM Wako Pure Chemical Corporation Cat# 37326-33-3
CELLection Biotin Binder Kit Invitrogen Cat#115332
Biotinylated Lotus Tetragonolobus Lectin (LTL) VECTOR Laboratories Cat#B-1325
b-hydroxybutylate Sigma Aldrich Cat#BCBM0192V
Rapamycin LC Laboratories Cat#53123-88-9
Empagliflozin Boehringer Ingelheim GmbH N/A
1,3-butanediol Sigma Aldrich Cat#SHBH3364V
Phosphatase inhibitor cocktail tablets Sigma Aldrich Cat#4906837001
Protease inhibitor cocktail tablets Sigma Aldrich Cat#11836145001
Tamoxifen Sigma Aldrich Cat#T4658-5G
Ethanol Nakarai tesque Cat#14713-53
Methanol FUJIFILM Wako Pure Chemical Corporation Cat#137-01823
0.5w/v% Methyl Cellulose 400 Solution, Sterilized FUJIFILM Wako Pure Chemical Corporation Cat#133-17815
Peroxidase Stain DAB kit Nakarai tesque Cat#25985-50
Cellstain-DAPI solution Wako Pure Chemical Corporation Cat#342-07431
Critical Commercial Assays
LBIS Mouse Urinary Albumin Assay Kit (S-type) FUJIFILM Wako Shibayagi Corporation Cat# 638-25561
Urinary Creatinine ELISA Kit FUJIFILM Wako Pure Chemical Corporation Cat#301-35651
FFA assay kit FUJIFILM Wako Pure Chemical Corporation Cat#438-91691
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TG assay kit FUJIFILM Wako Pure Chemical Corporation Cat# 467-08994
LDL-C assay kit SEKISUI MEDICAL Cat#261701
Cystatin C measurement kit BioVendor Cat#291009200R
TACS 2 TdT DAB kit TREVIGEN Cat#29274M13
AMERIC-ATP kit (For animal study) AMERIC Cat#AT002
IntraCellular ATP assay kit (For cell culture study) TOYO INK GROUP Cat#IC2-100
RELAR medium CELL SCIENCE & TECHNOLOGY INSTITUTE Cat#2112P05
Glutest Neo Alpha Sanwa Kagaku Cat#GT1830
PRECISION XCEED (ketometer) Abbott Cat#XEGS335-P03AF
hspCas9 mRNA System Biosciences Cat#CAS500A-1
T7 gRNA SmartNuclease Synthesis Kit System Biosciences Cat#CAS510A-KIT
mMESSAGE mMACHINER T7 Kit Invitrogen Cat#AM1344
Experimental Models: Organisms/Strains
ApoE+/ mice Jackson Laboratory #002052
TSC1f/f mice Jackson Laboratory #005680
NDRG1-CreERT2 mice Endo et al., 2015 N/A
Hmgcs2/ mice This paper N/A
C57BL/6JJcl CLEA Japan N/A
BKS.Cg-m+/+Leprdb/Jcl (Db/m) CLEA Japan N/A
BKS.Cg-+Leprdb/+Leprdb/Jcl (Db/db) CLEA Japan N/A
Other
Polyvinylidene difluoride membranes Merk Millipore Cat#IPVH00010
2-dimentional laser blood flow imager, OMEGAZONE OMEGAWAVE Cat#OZ-3
Nikon Eclipse 90i (microscope) Nikon Corporation N/A
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific N/A
Image-Pro Plus (version 7.0) Media Cybernetics N/A
SPSS software (version 22) IBM N/A
White Light Laser Confocal Microscope Leica TCS SP8 X Leica MICROSYSTEMS N/A
COMPACT pH METER (LAQUAtwin-pH-22B) HORIBA Advanced Techno N/A
BP-98A-L (Blood pressure monitor) Softron N/A
Transmission Electron Microscope H-7500 Hitachi High-Tech Corporation N/A
Scanning Electron Microscope JSM-7800F JEOL N/A




Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Shinji
Kume (skume@belle.shiga-med.ac.jp).
Materials Availability
Mouse lines generated in this study (Hmgcs2/ mice) are available from the lead contact upon request.
Data and Code Availability
There are neither new datasets/code generated nor restrictions for use of the materials in the paper.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Models
All experimental protocols were approved by the Gene Recombination Experiment Safety Committee and Research Center for An-
imal Life Science (RCALS) at Shiga University of Medical Science. All mice were housed in a temperature-controlled environmentCell Metabolism 32, 404–419.e1–e6, September 1, 2020 e2
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Article(23C) with a 12-h light and 12-h dark (20:00–08:00) photoperiod, and cared for in facilities operated by Research Center for Animal
Life Science at Shiga University of Medical Science. CLEA Rodent Diet (#CE-2, CLEA Japan) was used as the standard chow in the
center. Mice housed in the center are regularly tested for health conditions, including microbacterial inspection.
Eight-week old male and female ApoE+/ mice were purchased from Jackson Laboratory (#002052, B6.129P2-Apoetm1Unc/J; Bar
Harbor, ME, USA). ApoE/ mice (C57BL/6 background) were generated by crossbreeding male and female ApoE+/ mice. Ten-
week-old male ApoE/ mice and their littermate controls ApoE+/+ mice were fed a 60% high-fat diet (HFD) or normal diet (ND),
respectively, for 24 weeks, and atherosclerosis, renal blood flow, renal histology, and renal function were examined after sacrifice.
For the study of 1,3-butanediol (1,3-BD) treatment in HFD-fed ApoE/ mice, 1,3-BD was administered by preparing a HFD con-
taining 20% 1,3-BD solution (Sigma Aldrich, St. Louis, MO, USA). First, 10-week old male ApoE/ mice were fed a 60% HFD for
16 weeks (n = 13), and then fed either a 1,3-BD-containing HFD (n = 6) or a simple HFD (n = 7). Age-matched ND-fed ApoE+/+
mice were used as a control group (n = 5).
For the study of empagliflozin treatment in HFD-fed ApoE/ mice, 10-week old male ApoE/ mice were fed a 60% HFD for
16 weeks (n = 16) and then orally administrated with empagliflozin (30 mg/kg/day, n = 8) or vehicle solution (n = 8) for 8 weeks. In
this study, oral gavage was performed at 17:00, and all mice were fasted from 09:00 to 17:00 to match the rhythm of their daily lives
to general human subjects. Age-matched ND-fed ApoE+/+ mice were used as a control group (n = 5). Empagliflozin compound was
first resolved in methanol (30 mg/mL) and then diluted in 0.5% (w/v) methylcellulose solution at a final concentration of 3 mg/mL.
Methanol in 0.5% (w/v) methylcellulose was used as the vehicle.
Amousemodel harboring a deletionmutation in exon 2 of themouseHmgcs2 genewas generated using the Crispr/Cas9 system at
Unitech (Chiba, Japan). Cas9mRNA and single guide RNAs (sgRNAs) were synthesized as follows. Cas9mRNAwas prepared in vitro
from linear DNA templates using the CAS500A-1 hspCas9 mRNA (System Biosciences, Palo Alto, CA), and sgRNAs were generated
using the CAS510A-KIT T7 gRNA SmartNuclease Synthesis Kit (System Biosciences) and AM1344mMESSAGEmMACHINER T7 Kit
(Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. The following sequences were used for sgRNA syn-
thesis: sgRNA1, TGGAACGCACAAAGCTGCCG; sgRNA2, GTGCCTGCAGTGGTACAGA. Cas9 mRNA and sgRNAs (CAS9 mRNA:
gRNA1gg:gRNA2cc = 2:1:1) were microinjected into fertilized embryos of C57BL/6J mice. Mouse lines with mutations in the mouse
Hmgcs2 gene were confirmed. Among these, one mouse line with a 38-bp deletion mutation in exon 2, which led to a frameshift and
subsequent complete deletion of Hmgcs2 protein synthesis, was selected for use in our study. Mutations inHmgcs2were confirmed
by Sanger sequencing analyses (Bionics, Gangwon-do, South Korea). Homozygous Hmgcs2/ mice were born from a heterozy-
gous intercross and used for phenotypic analyses in parallel with age- and sex-matched wild-type littermates as a control group.
All mice were genotyped 2 weeks after birth by PCR with specific primers (forward, 50-AATATGTGGACCAAACTGACCTG-30 and
reverse, 50-CTTGGACTTGTCAATGATGGTCT-30). Animals were housed according to their sex after weaning. Functional deletion
of the gene was confirmed by a deficient ketone body increase during 36-h fasting in Hmgcs2/ mice. Double-knockout mice lack-
ing murine ApoE and Hmgcs2 genes were generated by crossbreeding male and female ApoE/-Hmgcs2+/ mice.
For the study of empagliflozin treatment in ApoE/mice and ApoE/mice lacking theHmgcs2 gene, 10-week old male ApoE/
mice (n = 15) andApoE/mice lacking theHmgcs2 gene (n = 7) were fedwith a 60%HFD for 16weeks. Subsequently,ApoE/mice
fed a HFD for 16 weeks were treated with either empagliflozin (30 mg/kg/day, n = 7) or vehicle solution (n = 8). ApoE/ mice lacking
the Hmgcs2 gene were all treated with empagliflozin (30 mg/kg/day). The protocol for empagliflozin administration was as
described above.
Tsc1f/f mice (C57BL/6 background) were purchased from Jackson Laboratory (#005680, STOCK Tsc1tm1Djk/J). The Ndrg1CreER
mouse model (C57BL/6 background) was previously established by Motoko Yanagita’s lab (Endo et al., 2015). Tsc1f/f-Ndrg1CreER
mice were generated by crossbreeding female Tsc1f/f mice and male Ndrg1CreER mice. Subsequently, female Tsc1f/f mice and
male Tsc1f/+ mice carrying Ndrg1CreER were crossbred to obtain Tsc1f/f mice carrying Ndrg1CreER. Eight-week-old Tsc1f/f mice
and Tsc1f/f mice carrying Ndrg1CreER were intraperitoneally injected with 150 mg/kg/day of tamoxifen for 5 consecutive days.
Male tamoxifen-injected Tsc1f/f mice were used as controls. To evaluate survival rates, male kidney-specific Tsc1/ mice (Kid-
ney-Tsc1/ mice; tamoxifen-injected Tsc1f/f mice carrying Ndrg1CreER) were divided into two groups: 1,3-BD treatment (n = 10)
and non-treatment (n = 10). 1,3-BD treatment was started at the time of tamoxifen-induced Cre induction. Survival rates were as-
sessed until 8 weeks after tamoxifen injection. In another series of studies, living PTEC-Tsc1/ mice treated with or without 1,3-
BD were examined for renal phenotypes in three groups (n = 5 per group), and were analyzed at 4 weeks after tamoxifen-induced
Cre induction. To examine the effect of empagliflozin, male Kidney-Tsc1/ mice were treated with or without empagliflozin (n = 6
for analyzing renal phenotype at 4 weeks after tamoxifen injection, and n = 10 for evaluating survival rate). The protocol for empagli-
flozin gavage was as described above.
Eight-week old db/db mice (BKS background) were purchased from Clea Japan (Tokyo, Japan) and used for 1,3-BD treatment
experiments. 1,3-BD was administered by preparing ND containing a 20% 1,3-BD solution. Eight-week old male diabetic db/db
mice were fed ND for two weeks and then fed either a 1,3-BD-containing diet (n = 6) or simple ND (n = 6) for a further 12 weeks.
Age-matched ND-fed db/m mice were used as a control group (n = 6).
To study empagliflozin treatment of db/db mice, eight-week-old male db/db mice were fed ND for two weeks and then orally
administrated with empagliflozin (30 mg/kg/day, n = 6) or vehicle solution (n = 6) for 12 weeks. In this study, oral gavage was per-
formed at 17:00, and all mice were fasted from 09:00 to 17:00 to match the rhythm of their daily lives to general human subjects.
Age-matched db/m mice fed ND were used as a control group (n = 6).e3 Cell Metabolism 32, 404–419.e1–e6, September 1, 2020
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After a week, ligation-based 2/3 nephrectomy in the left kidney was performed on eight-week-old male C57BL/6 mice as a first oper-
ation. The superior and inferior 1/3 parts of the kidney were ligated with a 3-0 silk suture string. Seven days later, the right kidney was
removed. For the sham surgery, the same surgical procedures were performed, including exposure of the kidney, dissection of tis-
sue, and wound closure, but without the pole ligation of the left kidney or removal of the right kidney. Nine-week-old operated mice
were treated with 1,3-BD or empagliflozin using the same protocol as described above for the db/dbmouse study. Seven mice were
prepared for each mouse group.
For sacrificing, mice were anesthetized, and blood samples were drawn by ventricular puncture. Next, mice were perfused with
phosphate-buffered saline (PBS) and the unilateral kidney was removed. Finally, mice were perfused with fixative buffer (4% para-
formaldehyde in 0.1M phosphate buffer), and the fixed kidneys and aorta were removed. Blood samples were collected into heparin-
coated tubes and centrifuged to collect plasma samples, whichwere stored at80Cuntil assays. Renal cortexes were isolated from
kidneys (removed after PBS infusion) and frozen in liquid nitrogen, while frozen cortexes were used for immunoblots and ATP mea-
surements. Fixed kidney tissues were used for hematoxylin and eosin (H&E) staining, immunostaining, and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining. For en face aorta analyses, aorta samples were pinned on a black wax surface,
fixed, and stained with Oil-Red O. Details for each assay are described in the Method Details section.
Primary Cell Cultures
All cells were grown at 37C in a 5% CO2 humid atmosphere. Male HFD-fed ApoE/ mice and male ND-fed ApoE+/+ mice aged
34weeks, as well as 12-week oldmale Tsc1f/fmice carrying Cre recombinase in PTECs, were used for the PTEC isolation study. After
anesthetization, the kidneys were immediately removed and placed in cold (4C) phosphate buffer. The renal capsule was removed
and the kidney was sagittally cut into two halves. The medulla was dissected and discarded from each half. The remaining cortical
tissue was minced and digested in Hanks’ balanced salt solution containing collagenase type II (Life Technologies, Carlsbad, CA,
USA; 200 units/mL) and hyaluronidase (Wako Pure Chemical Industries, Osaka, Japan; 0.2%). Tubules were incubated at 37Cwhile
rotating for 2 h. After digestion, the tubule suspension was centrifuged at 200 3 g for 5 min. The selection of PTECs was performed
using a CELLection Biotin Binder Kit (Invitrogen) and biotinylated Lotus tetragonolobus agglutinin lectin (LTL) (Vector Laboratories,
Burlingame, CA, USA). Isolated PTECs were resuspended in RELAR medium (Cell Science & Technology Institute, Sendai, Japan)
and seeded into culture dishes.
METHOD DETAILS
En Face Analysis of Aorta
Isolated aorta samples placed on a black wax surface for en face analysis were fixed in 4% paraformaldehyde, 5% sucrose, and
20 mmol EDTA (pH 7.4). Lipids were visualized with standard Oil-Red O staining (Thermo Fisher Scientific, Waltham, MA, USA). Im-
ages were acquired, and the percentage of aortic area stained red was determined using image analysis software (Image Pro, Media
Cybernetics, Rockville, MD, USA). Data are expressed as the percentage of red-colored area to the total observed aortic area.
Renal Blood Flow Measurements
Renal blood flow in living mice were measured using a laser speckle blood flow imager (Omega Zone; Omegawave, Espoo, Finland)
under anesthesia with 1.5% isoflurane. For each mouse, renal blood flow was measured in three different areas within one kidney,
and the average value was taken as the renal blood flow of that individual.
Histology
The removed renal tissues were fixed with 4% paraformaldehyde for 24 h, dehydrated with a decreasing alcohol series (2 3 100%,
23 95%, 23 70%, 23 toluene) for 2 h each, and finally immersed in paraffin for 6 h twice. Paraffin-embedded renal samples were
sectioned (3 mm) and subjected to standard H&E and PAS staining. The stained sections were observed with a Nikon Eclipse 90i mi-
croscope (Nikon Corporation). From eachmouse, 20 glomeruli cut at their vascular poles were supplied for morphometrical analysis.
The glomerular tuft area (glomerular size) and the extent of the mesangial matrix (mesangial area) were determined by assessing the
PAS-positive, and the nuclei-free area in the mesangium was analyzed using a computer-assisted color image analyzer (Image-pro
plus v. 7, Nippon Roper, Tokyo, Japan).
For immunostaining, paraffin-embedded tissue sections were used. Endogenous peroxidases were blocked with 0.03% H2O2 for
10min and nonspecific bindingwas blockedwith 2%normal goat serum for 30min. Tissueswere incubatedwith primary antibody for
12 h at 4C, followed by incubation with ImmPRESS HRP Anti-Rabbit IgG Polymer Detection Kit (Vector Laboratories) according to
the manufacturer’s recommendations. Reactions were developed with Peroxidase Stain DAB kit (Nakarai Tesque, Kyoto, Japan) ac-
cording to the manufacturer’s instructions, and then slides were counterstained with hematoxylin. To analyze the stain-positive area
of fibronectin in glomerular and tubulointerstitial lesions and CD31-positive vascular density in the interstitium, a tissue photograph at
amagnification of 200was used, and the ratio of the area showing density higher than the lower limit of positivity was calculated using
Image-Pro Plus (version 7.0) (Media Cybernetics). For analyzing F4/80 positive cell number, nuclei number of F4/80-positive cells in
the interstitium were counted in a tissue photograph at a magnification of 200. For quantitative analysis, 20 areas were analyzed per
mouse kidney sample.Cell Metabolism 32, 404–419.e1–e6, September 1, 2020 e4
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instructions. At least 20 cortical areas at a magnification of 200 were imaged and numbers of TUNEL-positive cells in tubular cells
were counted. Data are expressed as numbers of TUNEL-positive cells per visual field.
For the immunofluorescent study, fixed kidney sections were preincubated with 2% BSA in PBS for 10 min at room temperature.
The samples were then covered overnight at 4C with the primary antibody in the pre-incubation solution. The sections were rinsed
three times with PBS, incubated with 2% goat serum in 2% BSA in PBS at room temperature, and then incubated for 1 h at 4C with
the secondary antibodies. After DAPI staining and subsequent rinsing with PBS, the sections weremounted usingmountingmedium.
The stained sections were imaged with a fluorescence microscope (White Light Laser Confocal Microscope Leica TCS SP8 X, Leica
MICROSYSTEMS, Wetzlar, Germany).
For electron microscopic analysis, after fixation with 2% osmium tetroxide, kidney tissues were dehydrated in a series of graded
ethanol preparations, ethanol was replaced with propylene oxide, and samples were embedded in epoxy resin. Ultrathin sections
were double-stained with uranyl acetate and lead. Transmission and scanning electron microscopic analyses were performed using
a Hitachi S-570 and H-7500 instrument (Hitachi, Tokyo, Japan).
Measurement of Urinary Albumin
Urine samples were collected over the course of 24 h usingmetabolic cages in whichmice were able to freely access food andwater.
Collected urine samples were centrifuged to remove debris. Clear supernatants of urine samples were used to measure albumin and
creatinine concentrations using an LBIS Mouse Urinary Albumin Assay Kit (S-type) (FUJIFILM Wako Shibayagi Corporation, Tokyo,
Japan) and Urinary Creatinine ELISA Kit (FUJIFILMWako Pure Chemical Corporation), respectively, according to the manufacturers’
instructions. Urinary albumin levels are reported as the ratio of urinary albumin to creatinine.
Measurement of Plasma Cystatin C
Plasma cystatin C levels were measured using a Cystatin C measurement kit (BioVender, Asheville, NC, USA) according to the man-
ufacturer’s instructions.
Measurement of ATP Levels in Renal Tissues
ATP concentrations in renal cortex samples were measured using an AMERIC-ATP Kit (AMERIC, Tokushima, Japan), according to
the manufacturer’s instructions. AUTO-LUMINOCOUNTER (Microtec, Funabashi, Japan) was used to measure luminescence. ATP
concentrations are expressed as the ratio of ATP concentration to tissue volume.
ATP Measurement in Cultured Cells
Seven days after seeding isolated cells, the cell culture medium was changed to Krebs-Ringer buffer without glucose and then either
200mM oleate or 10mM b-hydroxybutyrate (b-OHB) was added for 3 h. Untreated cells and cells treated with either oleate or b-OHB
were harvested with the extraction solution provided in the Intracellular ATP Assay Kit (Toyo Ink Group, Tokyo, Japan). ATP concen-
tration was measured using the kit according to the manufacturer’s instructions and expressed as the ratio of ATP concentration to
protein concentration in samples.
For cell culture study to examine the effect of Tsc1 deficiency on energy dependency, isolated PTECs from Tsc1f/f mice carrying
Cre recombinase were treated with/without tamoxifen (250 nM) to induce Cre expression from day 3 to day 7 after the isolation. For
rapamaycin treatment in the isolated PTECs from HFD-fed ApoE/ or TSC1f/f mice carrying Cre recopmbinase, the cells were
treated with rapamycin (1 pg/mL) for 24 h prior to assays of immunoblot or ATP measurement assay.
Immunoblots
Samples from the cultured cells seeded for 7 days after the isolation, and renal cortex samples were homogenized in ice-cold lysis
buffer containing 4% sodium dodecyl sulfate (SDS), 100 mM Tris (pH 6.8), phosphatase inhibitor cocktail 2 and 3, and protease in-
hibitor cocktail (Sigma Aldrich). Samples were vortexed and heated at 100C for 5 min, followed by vortexing and centrifugation to
remove undissolved debris. Protein concentrations were estimated bymeasuring the absorbance at 280 nm using a NanoDrop spec-
trometer (Thermo Fisher Scientific). Samples were resolved by SDS-polyacrylamide gel electrophoresis and transferred to polyviny-
lidene fluoride membranes (Immobilon; EMDMillipore, Burlington, MA, USA). After the membranes were blocked in 5% skim milk or
5% bovine serum albumin for 30min at room temperature, they were incubated with primary antibodies overnight at 4C, followed by
incubation with the corresponding secondary antibodies for 1 h at room temperature. Information on antibodies is listed in the Key
Resources Table. All primary antibodies were used at a dilution of 1:1000, with the exception of b-actin and pS6 (1:10000). Mem-
branes were washed and incubated with horseradish peroxidase-coupled secondary antibodies (1:1000; Amersham Biosciences,
Little Chalfont, UK). Blots were visualized with an enhanced chemiluminescence detection system (Perkin Elmer, Waltham, MA,
USA). Full gel scan images are shown in Figure S7.
Blood and Plasma Metabolic Parameters
Glucose and ketone body concentrations in blood collected from the tail vein were measured using a Glutest sensor (Sanwa Kagaku
Kenkyusho, Nagoya, Japan) and Ketometer (Abbott, Chicago, IL, USA), respectively. The plasma pHwasmeasured using a Compacte5 Cell Metabolism 32, 404–419.e1–e6, September 1, 2020
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ArticlepH meter (Horiba Advanced Techno, Kyoto, Japan). Free fatty acids, triglycerides, and low-density lipoprotein cholesterol were
measured using specific assay kits according to the manufacturer’s instructions.
Blood Pressure Measurement
Conscious mice were placed on a heated pad (37C) in a temperature-controlled quiet room to measure their blood pressure. After
5 min of resting conditions, the systolic blood pressure wasmeasured using a programmable tail-cuff sphygmomanometer (BP98-A;
Softron, Tokyo, Japan). Ten consecutive measurements of each mouse were collected, and the average values were calculated.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
For comparison among multiple groups, two-way ANOVA followed by Tukey’s post hoc analysis was used to determine the effect of
genotype and treatment. For comparison between two groups, an unpaired Student’s t test was used. Associations between plasma
cystatin C levels and renal ATP contents were analyzed using Pearson’s correlation coefficient. Survival parameters in the study us-
ing Tsc1/ mice were determined using the Kaplan-Meier method and compared using log-rank tests. In all analyses, Prism 8
version 4.1 (GraphPad) was used, and p values < 0.05 were considered statistically significant. Experimenters were not blinded to
the treatment or genotypes of animals; however, semiquantitative analysis of renal histology was conducted blinded. Exclusion
criteria were based on animal well-being at the beginning of the study. No animals were excluded from this study. No power analysis
was performed to determine the sample size. The sample size in each study was based on experience with previous studies employ-
ing DKD animals and knockout mice in our lab.Cell Metabolism 32, 404–419.e1–e6, September 1, 2020 e6
